PCVX

VaxcyteC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

30%

Probability

Target price

$74.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$61.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

B-

Bear case

20%

Probability

Target price

$39.00

Analysis reference price unavailable

Analysis 2026-08-17 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-08-17

AI commentary

The Q2 company release provides concrete operating evidence and a modest external EPS beat, but the later post-earnings read-through remains mixed rather than decisively positive. Tracked analyst actions included both a Zacks upgrade and conflicting Buy/Sell coverage, while the available price record shows $58.07 at the August 14 close, down 1.34% that day, without a clean release-to-date attribution. Keep this as a cautious catalyst-monitoring situation rather than a high-conviction short-term trade. [#PR-EARNINGS-2026-08-05] [PCVX analyst ratings](https://www.pricetargets.com/NASDAQ/PCVX) [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

RankAlpha Sentiment Codex - 2026-08-17

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-08-05catalystQ2 EPS modestly beat external consensusMedium impact

Vaxcyte filed its Q2 results release in an 8-K; secondary earnings data report EPS of -$1.97 versus -$2.06 consensus, a $0.09 beat, while revenue comparison was unavailable. [#SEC-8K-2026-08-05] [#PR-EARNINGS-2026-08-05] [PCVX Q2 2026 earnings report](https://www.marketbeat.com/earnings/reports/2026-8-5-vaxcyte-inc-stock/)

2026-11-15eventOPUS-1 Phase 3 topline data remains the key near-term readoutHigh impact

The Q2 update says all three VAX-31 adult Phase 3 trials are fully enrolled and OPUS-1 topline safety, tolerability, and immunogenicity data are expected in Q4 2026, supporting the planned BLA path if successful. [#PR-EARNINGS-2026-08-05] [#SEC-8K-2026-08-05]

2026-11-15eventOPUS-2 and OPUS-3 supportive Phase 3 readoutsHigh impact

Management expects results from the coadministration and previously vaccinated-adult studies in the first half of 2027; positive results could broaden label support and commercial positioning. [#PR-EARNINGS-2026-08-05]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-08-17 • Updated nightlySource: Internal modelMethodology